Allen Burton, M.D.

Burton, a distinguished and board-certified anesthesiologist with an added certification in pain management brings nearly 20 years of experience in patient care to Abbott alongside a strong background leading large scale clinical research programs.

 

He  is Medical Director of Abbott’s Neuromodulation division, inclusive of Abbott’s and pain management product portfolios. In this role, Dr. Burton focuses on advancing therapeutic options and oversees the division’s research and design, marketing and commercialization strategy, and clinical research.

 

Dr. Burton joined Abbott (formerly St. Jude Medical) in October 2015 and served as principal investigator for ACCURATE and SUNBURST trials. Prior to Abbott, he served as Chairman of the Department of Pain Medicine at the University of Texas MD Anderson Cancer Center from 2000-2011. From 2011 until August 2015, Dr. Burton practiced privately with Houston Pain Associates, where he directed clinical research and participated in many clinical trials.

 

“We’re at a crossroads for addressing chronic pain and opioid use in America. Neurostimulation therapy can provide superior pain relief, allowing chronic pain patients to reduce or stabilize the long-term use of opioids and get back to living healthier lives.”

 

Abbott is the global chronic pain market leader. The company’s  Proclaim series includes devices designed to deliver SCS for the treatment of chronic pain, and dorsal root ganglion (DRG) stimulation for patients seeking relief from causalgia — nerve pain following surgery or injury — and complex regional pain syndrome (CRPS). The Proclaim DRG Neurostimulation System is the first and only neurostimulation device approved only for CRPS. The Proclaim platform’s Bluetooth® wireless technology and iOS‡ software offers patients an intuitive therapy experience. The Proclaim SCS System is also the first upgradeable and recharge-free spinal cord stimulation system capable of delivering both tonic stimulation and Abbott’s proprietary BurstDR stimulation waveform, a superior therapy designed to more closely mimic how pain signals travel to the brain. The company’s Invisible Trial System is a discreet, app-based and wireless system that leverages Apple‡ iPod touch‡ mobile digital devices to help patients evaluate SCS therapy.

 

Dr. Burton obtained his Bachelor of Science at the University of Notre Dame, Medical Doctorate at Baylor College of Medicine, and completed his residency at Brigham and Women’s Hospital, Harvard Medical School. He has published more than 50 peer-reviewed articles and authored two text books, taught and lectured nationally and internationally, and played an active leadership role among numerous pain societies and editorial boards.